报价延迟最少15分钟:2025/08/26 17:18 EDT
盘后时段
|
||||
|
0.9299 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.93
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.18/-0.11
|
|
企业价值
83.32M
|
| 资产负债 |
|
每股账面净值
0.18
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
35.59M
|
|
每股收益
0.48
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/08/26 17:18 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR. |
